GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Marker Therapeutics Inc (FRA:GX1) » Definitions » Interest Paid

Marker Therapeutics (FRA:GX1) Interest Paid


View and export this data going back to . Start your Free Trial

What is Marker Therapeutics Interest Paid?

Interest Paid only applicable to companies reporting Cash Flow from Operations in direct method.


Marker Therapeutics Business Description

Traded in Other Exchanges
Address
9350 Kirby Drive, Suite 300, Houston, TX, USA, 77054
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets. It is also developing peptide-based immunotherapeutic vaccines for the treatment of metastatic solid tumors, as well as PolyStart.